TP53 and neoplasm: In line with previous studies [5, 10], p53 immunohistochemistry (mouse monoclonal, clone DO7, 1:300; Novocastra, Newcastle, UK) revealed that the EBV-positive and -negative tumor areas exhibited wild-type and mutant-type p53 immunostaining patterns, respectively (Fig. 3A and B).